KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Invested Capital (2016 - 2025)

Sarepta Therapeutics has reported Invested Capital over the past 15 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Invested Capital at $1.2 billion for Q4 2025, down 56.66% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (down 56.66% YoY), and the annual figure for FY2025 was $1.2 billion, down 56.66%.
  • Invested Capital for Q4 2025 was $1.2 billion at Sarepta Therapeutics, down from $1.4 billion in the prior quarter.
  • Over the last five years, Invested Capital for SRPT hit a ceiling of $2.7 billion in Q4 2024 and a floor of $1.0 billion in Q3 2021.
  • Median Invested Capital over the past 5 years was $1.7 billion (2021), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Invested Capital: soared 97.1% in 2022 and later tumbled 56.66% in 2025.
  • Sarepta Therapeutics' Invested Capital stood at $1.5 billion in 2021, then rose by 29.33% to $1.9 billion in 2022, then rose by 8.71% to $2.1 billion in 2023, then grew by 27.06% to $2.7 billion in 2024, then tumbled by 56.66% to $1.2 billion in 2025.
  • The last three reported values for Invested Capital were $1.2 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.